DOCSLIB.ORG

30 November 1994 MARRAKESH AGREEMENT ESTABLISHING THE

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
30 November 1994 MARRAKESH AGREEMENT ESTABLISHING THE ACCORD GENERAL ACUERDO GENERAL SUR LES TARIFS DOUANIERS 5 ^ SOBRE ARANCELES ADUANEROS ET LE COMMERCE VJtBÀEU Y COMERCIO GENERAL AGREEMENT ON TARIFFS AND TRADE Centre William Rappard Téléphone: (41 22) 739 51 11 Rue de Lausanne 154 Ligne directe: (41 22) 739 5076 Case postale Telefax: (41 22) 731 42 06 CH - 1211 Genève 21 Télex: 412 324 GATT CH Télégramme: GATT, GENÈVE Référence: GLI/303 30 November 1994 MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION DONE AT MARRAKESH ON 15 APRIL 19199S 4 PROCES-VERBAL OF RECTIFIC In documents G/RS/6 and G/RS/7 proposed rectification*ttiorSto Schedule XXXVIII - Japan annexed to the Marrakesh Protocol to the General Ajffeehoent on Tariffs and Trade 1994 were circulated to the Participants in the Uruguay Roand ofjvlultilateral Trade Negotiations. Considering that no objections to these rectifications ravebeen raised during the thirty-day period established for such action, these rectifications have been approved. The relevant texts are annexed hereto. I J Acting as depositary of the Marrakesh Agreement Establishing the World Trade Organization, I have caused these rectifications to be made in the authentic text and have initialled these rectification:tiîLcatior s in the relevant schedule annexed to the Marrakesh Protocol. In witness whereof I have signed the present Procès-Verbal of Rectification, drawn up in the English, French anid SpanisSper h languages, on 30 November 1994. O Peter D. Sutherland O Director-General 94-2611 Let/1953 Accord générât sur les Tarif* douanier* et le Commerce General Agreement on Tariffs and Trade Page 2 MARRAKESH PROTOCOL TO THE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994 Schedule XXXVIII - Japan The following corrections should be made in "Schedule XXXVIII - Japan": 1. Notes to Schedule XXXVIII - Japan The current first sentence of paragraph 5 should be replaced by the sentence below: "Where a rate reduction of an ad valorem duty implemented in accordance with the provisions in paragraphs 2 and 3 above and the Notes to Sections l-A and II of Part I of this Schedule gives a rate with a decimal fraction of less than 0.1 per cent, such fraction shall be rounded to one decimal place (in the case of 0.05 per cent, the fraction is rounded to 0.1 per cent)." 2. Part I, Section II 1) Page 15, tariff item number 1521 The description of products shall be corrected as follows: "Vegetable waxes (other than triglycerides), beeswax, other insect waxes and spermaceti, whether or not refined or coloured." 2) Page 355, tariff item number 7801.91 The following description of products shall be inserted fortheHS subheading 7801.91 (there is no change in the national subheadings which fall under this HS subheading): "-- Containing by weight antimony as the principal other element" 3) Page 406, tariff item number 8483.60 An asterisk ("*") shall be put in column 1 to indicate that the product includes the item listed in the Attachment to Section II of Part I. 3. Attachment to Section II of Part I. page 1. tariff item number 7304.31 In the description of products, "cold-drawn or cold-rolled fittings, suitable for conducting (cold-reduced), with attached gases or liquids" shall be corrected as "cold-drawn or cold-rolled (cold-reduced), with attached fittings, suitable for conducting gases or liquids". 4. Annexes I. II and III to the Attachment to Schedule XXXVIII - Japan The attached revised pages containing corrections listed in document L/7430/Add.4 should replace the corresponding current pages of Annexes I, II and III ("Trade in Pharmaceutical Products"). Annex I MS Description IIS Doser iption Subheading Subhead ins 2922.19 treptllamine 2922.30 drinidene 2922.19 trolnltrale 2922.30 isomethadonc 2922.19 lroman tadinc 2922.30 kelamIne 2922.19 tromntamol 2922.30 levomethadone 2922.19 tu lobule nil 2922.30 mctamfepramonc 2922.19 voglibose 2922.30 methadone 2922.19 zuclomlfcnc 2922.30 nafenodone 2922.29 alentemol 2922.30 normethadone 2922.29 amlnoxytriphene 2922.41 lysine 292229 blalamlcol 2922.42 glutamic acid 2922.29 brolamfetamlne 2922.49 aceclofenac 2922.29 dezoc ine 2922.49 alanine 2922.29 dobutamine 2922.49 alaproclate 2922.29 dopamine 2922.49 alminoprofen 2922.29 dopexamine 2922.49 amincpllne 2922.29 gepefr Inc 2922.49 nmlnocaproic acid 2922.29 hydroxyamfelamIne 2922.49 amoxecalne 2922.29 ibopamlne 2922.49 araprofen 2922.29 levdobutamlnc 2922.49 aspartlc acid 2922.29 lomelralIno 2922.49 baclofen 2922.29 me thoxyphenamIne 2922.49 benzocaine 2922.29 mitoclomlne . 2922.49 benzonatate 2922.29 ox(dopamine 2922.49 betoxycalne 2922.29 pholedrine 2922.49 butacalne 2922.29 symct Inc 2922.49 calcium trisodlum penletatc 2922.29 toi te rodIne 2922.49 camylof In 2922.29 trlmoxaminc 2922.49 cctaben 2922.29 vetrabullne 2922.49 cetraxate 2nz2..in amfebutamnne 2922.49 chlorambuc i1 2922.30 amfeprnmone 2022.49 chloroprocalne 2922.30 cathlnone 2922.49 clofcnamlc acid 2922.30 coirIptylIne 2922.49 clormecaine 2922.30 dexnafenodone 2922.49 dextilidine IIS Description IIS Doser iption Subheading Subheading 2922.50 butopaminn 2922.50 ectpramldi1 2922.50 cIcloprolol 2922.50 egtazlc acid 2922.50 cInamolol 2922.50 ericolol 2922.50 cIrnmadol 2922.50 esmolol 2922.50 cliropamine 2922.50 etafenone 2922.50 clomi fennxide 2922.50 etanterol 2922.50 cloranolnl 2922.50 elilefrlne 2922.50 colterol 2922.50 e t ilef r Ine plvalatc 2922.50 corbadrlne 2922.50 etlroxate 2922.50 cyclopentolatc 2922.50 etofenamale 2922.50 decomlnol 2922.50 exaprolol 2922.50 dembrcxlne 2922.50 fedotozine 2922.50 denaverlnc 2922.50 fenalconlne 2922.50 denopamlne 2922.50 fenaralsal 2922.50 detanosal 2922.50 fenotcrol 2922.50 deterenol 2922.50 f lusoxolol 2922.50 dctrothyronine 2922.60 forfenimex 2922.50 dexfosfoserlne 2922.50 fosopamine 2922.50 dexpropranolol 2922.50 ganglefene 2922.50 dexsecoverlne 2922.50 guafecainol 2922.50 dextrothyroxine sodium 2922.50 gualac tarnIne 2922.50 dietlfcn 2922.50 hexobendlne 2922.50 di femerine 2922.50 hexoprenaline 2922.50 dlfeterol 2922.50 hydroxyprocaine 2922.50 dlmenoxado! 2922.50 hydroxytelracalne 2922.50 dlmetofrIne 2922.50 Ibulerol 2922.50 dloxcthedrln 2922.50 Idropranolol 2922.50 dloxlfedrIne 2922.50 Indenolol 2922.50 dlpivefrIne 2922.50 Iproxamlne 2922.50 diprafenone 2922.50 Isoetarine 2922.50 divabuterol 2922.50 Isoprenaline 2922.50 drbloxlfene 2922.50 Isoxsuprine 2922.50 droxldopa 2922.50 ketocalne 14 IIS Description IIS Dcscr ipt ion Subheading Subhead Inn 2934.90 11bene last 2934.90 I Ipindole 2934.90 tibrofan 2934.90 tIprinast 2934.90 ticlatone 2934.90 tiquizium bromide 2934.90 ticlopidine 2934.90 t isocromidc 2934.90 tlemonium iodide 2934.90 tivanldazole 2934.90 tienl1ic ac id 2934.90 tlxadll 2934.90 tlenocarblnc 2934.90 tizabrIn 2934.90 tlenopraminc 2934.90 tizanidine 2934.90 tlenoxolol 2934.90 toloxatone 2934.00 t i femoxonc 2934.90 topotecan 2934.90 tlfluadorn 2934.90 lozallnone 2934.90 tIflucarbine 2934.90 traboxoplnc 2934.90 t1letamlne 2934.90 tran tel inIum bromide 2934.90 tlIon Isole 2934.90 traxanox 2934.90 tilozcplne 2934.90 trlclrIblnc 2934.90 tlmelotem 2934.90 triflurldlnc 2934.90 timepldlun bromide 2934.90 trimctaphan cams Mate 2934.90 timolol 2934.90 trimethadlone 2934.90 tlnabinol 2934.90 trlmetozine 2934.90 tInofedrinc 2934.90 trltiozine 2934.90 tinorIdine 2934.90 tritoqualInc 2934.90 tloclomarol 2934.90 trlxolane 2934.90 tloconazôle 2934.90 trofosfamlde 2934.90 tiodazosln 2934.90 tropateptne 2934.90 tiodonlum chloride 2934.90 troquldazole 2934.90 tloplnoc 2934.90 tubulozole 2934.90 tlosplrone 2934.90 tulopafant 2934.90 t loxacln 2934.90 ularitide 2934.90 tloxaprufen 2934.90 utibaprll 2934.90 I1oxolone 2934.90 utlbaprllat 2934.90 tlpenlosln 2934.90 valperInol 2934.90 lidrpId inc 2934.90 vanltlolIdo 2934.90 tlpctropIum bromide 2934.90 vapreotlde 73 Annex 11 Prefixes, and Suffixes for Salts. Eslers and Hydrates of INNs ACETATE BORATE CYCLOHEXYlAMMONIUM ACETONIDE BROMIDE C YCLOIIEX YLPROPIONATE l-ACETOXYETHYL BUTYL DECANOATE ACETYLSAUCYIATE t-BtrrYL DIACETATE ADIPATE t-BUTYL ACETATE DI AMMONIUM ALLYL tert-BUTYL ACETATE DIBENZOA1E ALLYL BROMIDE tertiary BUHL ACETATE DIBUTYRATE ALLYL IODIDE tertiary BUTYLAMINE DICHOLINE , ALUMINIUM t-BUTYL ESTER DICYCLOHEX YLAMMONIUM AMINOSALiaLATE tert-BUTYL ESTER DIETHYLAMINE AMMONIUM tertiary BUTYL ESTER DIETHYLAMMONIUM AMMONIUM FUS I DATE BUTYLATE DIFtJROATE ANTIPYRATE BUTYLBROMIDE DIHYDRATE ARGININE BUTYRATE DIHYDROBROMIDE ASOORBATE CALCIUM DIHYDROatLORIDE AXETIL CALCIUM CIIIJORIDE DIHYDROa«X)RIDE BARBITURATE CALCIUM DIHYDRATE PHOSPHATE BENZENESULFONATE CAMPHOR-10-SULPHONATE DIHYDROGEN CITRATE BENZOAŒTATE CAMPHOHATE DllfYDROGEN PHOSPHATE BENZYL CAMPHORSUFONATE DlirYDROXYBENZOATE BENZYL BROMIDE CAMS ILATE DIMALATE BENZYL IODIDE CAMSYLATE DI MAI FATE BESILATE CAPROATE DIMALONATE BESYLATE CARBAMATE DIMESILATE 111 QUI NATE CARBONATE DINITRATE BIS (HYDROGEN MALAIT!) CHI OR IDE DINITROBENZOAIK BISOIYDROGEN MALEATE) 8-a ILOROIl IEOPIIYLLINA1E DIOXIDE BIS(HYDROGEN MALONATE) CHOLINE DIPHOSPHATE BIS(PHOSPIIATE) CINNAMATE DIPROPIONATE BISMUTH CITRATE DISODIIIM BITARTRATE CYCLOHEXANEPROPIONATE DI SODIUM PHOSPHATE I MONONITRATE POTASSIUM TEBWATE N-CYCLOHEXYLSUI .PHAMA TE POTASSIUM SULFATE lEOCLATE N-OXIDE HYDROCHIJORIDE PROPIONATE TETRAHYDRATE NAFATE PROPIONATE DODECYL SULPHATE TETRAHYDROPimiAUTE NAPADIStlATE PROPIONATE LAURYL SULFATE TETRASODIUM NAPADISYLATE PROPYL THEOCLATE 1.5-NAPimiALENED I SULFONATE PROPYL ESTER THIOCYANATE 2-NAPHTHALENESULF0NA1E PYRIDY1 ACETATE P-TOLUENESULFONATE NAPS ILATE QUINATE TOSILATE NAPSYLATE RESINATE TOSYLATE NICOTINATE SAOCHARATE TRIFLUOROACETATE NITRATE SALICYIATE TRIHYDRATE NITROBENZOATE SALICYLOYLACETATE
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Novel Derivatives of Bio-Affecting Phenolic Compounds and Pharmaceutical Composition Containing Them
    Europaisches Patentamt European Patent Office © Publication number: 0046 270 A1 Office europeen des brevets ™ EUROPEAN PATENT APPLICATION @ Application number: 81106277.7 © Int. CI.3: C 07 C 103/78, C 07 C 93/26, C 07 C 69/24, C 07 C 1 53/07, @ Date of filing: 12.08.81 C07C 69/28 // C07C1 25/065 <§) Priority: 13.08.80 US 177825 © Applicant: INTERx RESEARCH CORPORATION, 2201 West 21 st Street, Lawrence Kansas 66044 (US) © I nventor : Bodor, Nicholas S., 31 5 Southwest 91 st Street, ® Dateofpublicationofapplication:24.02.82 S^^S^mHariMBM Bulletin m/b Terrace, Gainesville, Florida 32605 (US) Inventor: Pogany, Stefano A., 520 Louisiana Street, Lawrence Kansas 66044 (US) @ Designated Contracting States : AT BE CH DE FR GB IT ® Representative: Abitz, Walter, Dr.-lng. et al, Abitz, Mori, LI LU NL SE Gritschneder P.O. Box 86 01 09, D-8000 Munchen 86 (DE) Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them. Novel@ Novel transient prodrug forms of bio-affecting phe- amyl, CH2ONO2,CH2ON02, -CH2OCOR2 or any non-heterocyclic nolic compounds are selected from the group consisting of member of the group defined by R2Rz above; and n.isn is at least those having the structural formula (I): one and equals the total number of phenolic hydroxyl functions comprising the non-steroidal bioaffecting phenol o etherified via a R2COXCH(R3)0-moiety; those having the structural formula (II): R2-C-X-CH-0- (I) I O R, II R2-C-X-CH-0- -RM-i-O-C-R2 (II) wherein X is O, S or NR5 wherein R5 is hydrogen or lower alkyl;alky!;
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • Nine Prohibited Stimulants Found in Sports and Weight Loss
    Clinical Toxicology ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/ictx20 Nine prohibited stimulants found in sports and weight loss supplements: deterenol, phenpromethamine (Vonedrine), oxilofrine, octodrine, beta-methylphenylethylamine (BMPEA), 1,3-dimethylamylamine (1,3-DMAA), 1,4-dimethylamylamine (1,4-DMAA), 1,3- dimethylbutylamine (1,3-DMBA) and higenamine Pieter A. Cohen, John C. Travis, Céline Vanhee, Dana Ohana & Bastiaan J. Venhuis To cite this article: Pieter A. Cohen, John C. Travis, Céline Vanhee, Dana Ohana & Bastiaan J. Venhuis (2021): Nine prohibited stimulants found in sports and weight loss supplements: deterenol, phenpromethamine (Vonedrine), oxilofrine, octodrine, beta-methylphenylethylamine (BMPEA), 1,3- dimethylamylamine (1,3-DMAA), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylbutylamine (1,3- DMBA) and higenamine, Clinical Toxicology, DOI: 10.1080/15563650.2021.1894333 To link to this article: https://doi.org/10.1080/15563650.2021.1894333 View supplementary material Published online: 23 Mar 2021. Submit your article to this journal Article views: 22748 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=ictx20 CLINICAL TOXICOLOGY https://doi.org/10.1080/15563650.2021.1894333 BASIC RESEARCH Nine prohibited stimulants found in sports and weight loss supplements: deterenol, phenpromethamine (Vonedrine), oxilofrine, octodrine, beta- methylphenylethylamine (BMPEA), 1,3-dimethylamylamine
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 De Juan Et Al
    US 20110159073A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 de Juan et al. (43) Pub. Date: Jun. 30, 2011 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA A6F 2/00 (2006.01) (US); Signe E. Varner, Los (52) U.S. Cl. ........................................................ 424/427 Angeles, CA (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Featured is a method for instilling one or more bioactive (21) Appl. No.: 12/981,038 agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising con (22) Filed: Dec. 29, 2010 currently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a Sustained release Related U.S. Application Data delivery device comprising one or more bioactive agents in a (63) Continuation of application No. 1 1/175,850, filed on posterior region of the eye so that it delivers the one or more Jul. 5, 2005, now abandoned. bioactive agents into the vitreous humor of the eye; (B) instill ing (e.g., injecting or implanting) one or more bioactive (60) Provisional application No. 60/585,236, filed on Jul. 2, agents Subretinally; and (C) instilling (e.g., injecting or deliv 2004, provisional application No. 60/669,701, filed on ering by ocular iontophoresis) one or more bioactive agents Apr. 8, 2005. into the vitreous humor of the eye. Patent Application Publication Jun. 30, 2011 Sheet 1 of 22 US 2011/O159073 A1 Patent Application Publication Jun.
    [Show full text]